Bolt Biotherapeutics, Inc. (BOLT)
5.10
+0.04
(+0.79%)
USD |
NASDAQ |
Nov 20, 10:35
Bolt Biotherapeutics Cash from Operations (Quarterly) : -3.078M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -3.078M |
| June 30, 2026 | -6.54M |
| March 31, 2026 | -8.023M |
| December 31, 2025 | -7.156M |
| September 30, 2025 | -9.732M |
| June 30, 2025 | -9.597M |
| March 31, 2025 | -13.36M |
| December 31, 2024 | -14.43M |
| September 30, 2024 | -13.97M |
| June 30, 2024 | -16.14M |
| March 31, 2024 | -16.75M |
| December 31, 2023 | -14.26M |
| September 30, 2023 | -16.75M |
| June 30, 2023 | -15.11M |
| Date | Value |
|---|---|
| March 31, 2023 | -23.40M |
| December 31, 2022 | -17.95M |
| September 30, 2022 | -13.45M |
| June 30, 2022 | -20.79M |
| March 31, 2022 | -24.31M |
| December 31, 2021 | -17.79M |
| September 30, 2021 | -18.73M |
| June 30, 2021 | -3.986M |
| March 31, 2021 | -16.56M |
| December 31, 2020 | -12.89M |
| September 30, 2020 | -12.52M |
| June 30, 2020 | -12.26M |
| March 31, 2020 | -9.638M |
| December 31, 2019 | -6.262M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Caribou Biosciences, Inc. | -22.52M |
| Oncolytics Biotech, Inc. | -6.754M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 59.97M |
| Anixa Biosciences, Inc. | -1.77M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 4.00M |
| Free Cash Flow | -24.80M |
| Free Cash Flow Per Share (Quarterly) | -1.566 |
| Free Cash Flow to Equity (Quarterly) | -2.343M |
| Free Cash Flow to Firm (Quarterly) | -3.078M |
| Free Cash Flow Yield | -225.6% |